Osteoporosis Clinical Trials in Los Angeles

Showing 21-25 of 25 trials

Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception

NCT00139685

To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and following discontinuation of DMPA. Another group electing non-hormonal contraception or abstinence will be recruited as a reference population, across all study sites. The primary variable is BMD, measured by Dual Energy X-ray Absorptiometry (DXA). Secondary variables are: Total Body Composition\& Total Body Calcium (TBC), measured by Dual Energy X-ray Absorptiometry (DXA), and surrogate biologic BMD markers. Safety will be evaluated by adverse event reporting, laboratory evaluations, pregnancies, weight and vital signs.

ContraceptionBone Density

Pfizer350 participantsStarted Apr 1998

Los Angeles, California, United States • Palo Alto, California, United States • Torrance, California, United States +9 more locations

COMPLETEDPHASE419 miles

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444

This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.

Osteoporosis

Novartis110 participantsStarted Jan 2007

Phoenix, Arizona, United States • Buena Park, California, United States • Washington D.C., District of Columbia, United States +14 more locations

Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

Osteoporosis Trials in Other Cities

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

Other Conditions in Los Angeles